The biopharmaceutical sector welcomed a further 11 new IPO graduates in July, bringing the number to 39 that have started to trade on the U.S. markets this year. The companies going public last month collectively raised more than $2.5 billion and most of them made a favorable impression following their first day of trading, with the group increasing their share values by an average of 16%.

The share prices of blue-chip biopharmaceutical companies continued on their lackluster trajectory, which started in June and collectively lost ground last month, with the BioWorld Biopharmaceutical index slipping about 1.3% as investors took a break in order to digest the deluge of COVID-19 vaccine data released during the period and the impact on the bottom lines that the pandemic has exerted among those companies that have reported their second-quarter results.

Out of the $10.45 billion brought into the biopharma industry this year by way of collaborations with nonprofit entities or through grants, 80% is focused on COVID-19 therapeutics and vaccines.

BioWorld looks at translational medicine, including: Picturing molecular alterations; Fishing for druggable osteoporosis targets; First mouse-adapted strain of SARS-CoV-2; Transplanted iPSCs are best of both ApoE models; TXNIP inhibition nixes T2D; Degradation approach targets extracellular proteins; Tryptophan metabolites keep gut barrier strong; Honest placebos change brain potentials; Screening in serum yields active antibiotics.